natgillin/translations-raw huggingface dataset:
The process of production according to the invention comprises a cyclisation step of a corresponding linear peptide in protected form. 
Postupak pripreme u skladu s izumom obuhvaća korak ciklizacije odgovarajućeg linearnog peptida u zaštićenom obliku.
is hydrogen or C1-6alkyl; or R12 and R13 taken together with the nitrogen atom to which they are substituted form pyrrolidinyl; piperidinyl; morpholinyl; piperazinyl; piperazinyl optionally substituted with C1-6alkyl or C1-6alkylcarbonyl; imidazolyl; 
je vodik ili C1-6alkil; ili R12 i R13 uzeti zajedno sa atomom dušika na koji su supstituirani formiraju pirolidinil; piperidinil; morfolinil; piperazinil; piperazinil po izboru supstituiran sa C1-6alkil ili C1-6alkilkarbonil; imidazolil;
The use of the system according to claim 1, wherein said first composition further comprises a polymer. 
Upotreba sustava u skladu sa zahtjevom 1, naznačena time, što navedeni prvi sastav nadalje obuhvaća polimer.
Use according to claim 1 or pharmaceutical composition for use according to claim 2, wherein the pharmaceutical composition further comprises an additional therapeutic compound for use for treating cancer, said additional therapeutic compound being distinct from the population of metallic nanoparticles. 
Uporaba u skladu s patentnim zahtjevom I ili farmaceutski sastav za uporabu u skladu s patentnim zahtjevom 2, pri čemu farmaceutski sastav nadalje obuhvaća dodatnu terapijsku tvar namijenjenu za liječenje raka, navedena terapijska tvar je različita od populacije zlatnih nanočestica.
A double stranded RNAi agent for inhibiting expression of hepatitis B virus (HBV) in a cell, wherein said double stranded RNAi agent comprises a sense strand and an antisense strand forming a double-stranded region, wherein said sense strand comprises 5'-GUGUGCACUUCGCUUCACA -3' (SEQ IDNO:39), and said antisense strand comprises 5'-UGUGAAGCGAAGUGCACACUU -3' (SEQ ID NO:40), wherein substantially all of the nucleotides of said sense strand and substantially all of the nucleotides of said antisense strand are modified nucleotides, wherein said sense strand is conjugated to a ligand attached at the 3'-terminus, and wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker. 
Dvolančani RNAi agens za inhibiranje ekspresije virusa hepatitisa B (HBV) u stanici, naznačen time, da navedeni dvolančani RNAi agens sadržava sens lanac i antisens lanac koji tvori dvolančanu regiju, pri čemu navedeni sens lanac sadržava 5'- GUGUGCACUUCGCUUCACA -3 '(SEQ IDNO: 39) i navedeni antisens lanac sadržava 5'-UGUGAAGCGAAGUGUGCACACUU -3' (SEQ ID NO: 40), pri čemu su u osnovi svi nukleotidi navedenog sens lanca i u osnovi svi nukleotidi navedenog antisens lanca su modificirani nukleotidi, pri čemu je navedeni sens lanac konjugiran s ligandom vezanim na 3'-kraju i pri čemu je ligand jedan ili više GalNAc derivata vezanih preko bivalentnog ili trovalentnog razgrananog veznika.
The reaction mixture was then stirred for 16 hours at room temperature, filtered and evaporated under vacuum to yield a crude 1-imine solid. 
Reakcijska smjesa se tada miješa 18 sati na sobnoj temperaturi, filtrira se i ispari u vakuumu tako da se dobiva sirova 1-iminska kruta supstancija.
The method of claim 3 further comprising a method for preparing a compound of Formula IIb wherein R16 is OH, the method comprising: 
Postupak u skladu s patentnim zahtjevom 3 koji nadalje sadrži postupak za pripravu spoja Formule IIb, naznačen time, da je R'* OH, postupak se sastoji od: omogućavanja spoja Formule IIIb:
The capping group is intended not to be reactive towards a cell binding agent. 
CBA je sredstvo za vezanje stanice koje je protutijelo anti-DLL3;
The process of claim 1, further comprising recovering a reaction effluent comprising the reformed triacylglycerides-containing oil-carbon dioxide mixture. The process of claim 5, further comprising separating the reaction effluent to recover a first separation product comprising carbon dioxide and a second separation product comprising the hydrocarbons. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da nadalje obuhvaća odvajanje reakcijske otpadne tekućine (28) radi dobivanja prvog proizvoda odvajanja (64) koji sadržava ugljični dioksid i drugog proizvoda odvajanja (68) koji sadržava ugljikovodike.
An object of the present invention is more particularly a method as defined above, characterized in that said step of selecting at least one hybrid capable of metabolizing xylose and resistant to acetic acid comprises the steps of: 
Postupak u skladu s bilo kojim od patentnih zahtjeva 2 do 4, naznačen time što se navedeni korak odabira najmanje jednog hibrida koji može metabolizirati ksilozu i otporan je na octenu kiselinu sastoji u koracima:
Preparation of 1 L of sodium citrate approximately 0.2M: 58.82 g of sodium citrate were dissolved in a volumetric flask of 1 L and the solution was brought to the final volume with water for injection. 
Priprema 1L natrij citrata približno 0.2M: 58.82 g natrijcitrata otopljeno je u volumetrijskoj posudi od IL i otopina je dovedena do krajnje zapremine sa vodom za injekciju.
The inner part 60 has indentations 74, which the legs 75 of the U-shaped metal parts may grip into when clicking them onto there. FIG. 
Unutarnji dio 60 ima nazubljenja 74, u koje se mogu zahvatiti krakovi 75 metalnih dijelova koji imaju U-oblik, kada se ovi skočno pritisnu na njih.
centrifuging the suspension to obtain a pellet and supernatant; 
prema potrebi, sušenje supernatanta kako bi se dobio koncentrat topiv u lipidima.
(R)-pirlindole enantiomer or a pharmaceutically acceptable salt thereof for use in the therapeutic treatment or prevention of neuropathic pain. 
(R)-pirlindol enantiomer ili njegova farmaceutski prihvatljiva sol za terapiju ili prevenciju neuropatske boli.
wherein in is 1, 2, or 3, RF is H or C1-3alkyl, and RE is H, C1-3alkyl, or SO2CH3, and wherein each of the foregoing pyridyl, pyrrolidinyl, piperidinyl, and piperazinyl groups is optionally substituted at one or more carbon atoms with 1, 2, or 3 independent occurrences of R11, and at one or more substitutable nitrogen atoms with R12; 
NH RE LonH gdje je m jednak 1, 2 ili 3, R* jeHili C,3alkil, i R? je H, Crsalkil ili SOL2CH., i pri čemu je svaka od prethodno navedenih piridil, pirolidinil, piperidinil i piperazinil grupa izborno supstituirana na jednom ili više atoma ugljika sa 10
The method of claim 1, wherein R1 is chloro, and the remaining substitutents are as defined therein. 
je klor, i preostali supstituenti su kao što je prije tamo definirano.
The method for installation and laying of a waterproof liner according to claim 1 or 2, characterised by connecting opposite watertight flexible side flaps (26) of two adjoining waterproof panels (14; 14A) by a watertight zip fastener (28). 
Postupak ugradnje i polaganja vodonepropusne obloge u skladu s patentnim zahtjevom 1 ili 2, naznačen time, da se vodonepropusnim patentnim zatvaračem (28) spajaju suprotni vodonepropusni fleksibilni bočni preklopi (26) dviju susjednih vodonepropusnih ploča (14; 14A).
seeding the solution with purified staurosporine in a second solvent; and isolating the product. The process according to enumerated embodiment 4, wherein the first solvent is selected from benzyl alcohol, DMF, DMSO, acetic acid or PEG. 
(c) izoliranje taloga; pri čemu otapalo je odabrano od sljedećih: benzilni alkohol, DMF, DMSO, octena kiselina ili PEG; pri čemu je drugo otapalo odabrano od sljedećih: etanol, THF ili otopina etanola i vode.
R6, at each occurrence, is independently selected from: OH, halogen, CN, C1-4 alkyl, and C1-4 alkoxy. 
R* pri svakom pojavljivanju, je nezavisno odabran od: OH, halogen, CN, C14 alkil, i C14 alkoksi; i gdje spoj Formule (I) može biti izotopski obilježeno.
opposing side tabs on opposite sides of the leaflet, the side tabs being secured to the outflow end portion of the frame; 
suprotne bočne jezičke (366) na suprotnim stranama listića, pri čemu su bočni jezičci (366) učvršćeni za izlazni kraj okvira (12);
The T cell activating bispecific antigen binding molecule of item 21, wherein said one or more amino acid substitution is at one or more position selected from the group of E233, L234, L235, N297, P331 and P329 (EU numbering). 
iii) Fc domena obuhvaća jednu ili više aminokiselinskih supstitucija koje smanjuju vezivanje na Fc receptor i/ili efektorsku funkciju, pri čemu se navedena jedna ili više aminokiselinskih supstitucija nalazi na jednom ili više položaja odabranih iz skupine L234, L235 i P329 (EU numeriranje); i/ili
A compound according to claim 7 wherein the glucocorticosteroid is selected from budesonide, beclamethasone dipropionate, fluticasone propionate, ciclesonide or mometasone furoate. 
Spoj prema zahtjevu 11, naznačen time, da je glukokortikosteroid odabran od budesonida, beklametazon dipropionata, flutikazon propionata, ciklesonida ili mometazon furoata.
The humanized CD37-specific binding protein according to claim 1, wherein the light chain CDR1, CDR2 and CDR3 consist of the amino acid sequences of SEQ ID NOS: 61, 64 and 66, respectively; and wherein the heavy chain CDR1, CDR2 and CDR3 consist of the amino acid sequences of SEQ ID NOS: 63, 65, and 68, respectively. The humanized CD37-specific binding protein according to any one of the preceding claims, comprising: 
Humanizirani protein koji se specifično veže na CD37, ili protein koji se specifično veže na CD20, ili proizvodni artikl za upotrebu u liječenju karcinoma B-stanica ili autoimune bolesti navedeni u patentnim zahtjevima 1, 2 ili 3, pri čemu se laki lanci CDR1, CDR2 i CDR3 humaniziranog proteina koji se specifično veže na CD37 sastoje od aminokiselinskih slijedova iz SEQ ID NOS:61, 64 i 66, slijedom kojim su navedeni; i pri čemu se teški lanci CDR1, CDR2 i CDR3 sastoje od aminokiselinskih slijedova iz SEQ ID NOS: 63, 65 i 68, slijedom kojim su navedeni.
In one embodiment of the invention, said cancer is selected from breast cancer, Non-Hodgkins lymphoma, pancreatic cancer, hepatocellular cancer, gastric cancer, prostate cancer and lung cancer. In one particular embodiment, said cancer is breast cancer, more particularly luminal breast cancer. 
Uporaba spoja prema zahtjevu 1, ili njegove farmaceutski prihvatljive soli, naznačena time da je za pripravu lijeka za liječenje raka, gdje je rak odabran od raka dojke, ne-Hodgkinovog limfoma, raka gušterače, hepatocelularnog karcinoma, raka želuca, raka prostate i raka pluća,
A counter as described in embodiment 5 wherein said first engagement means is deflected radially outwardly after a predetermined degree of rotation of said first ring member, said predetermined amount of rotation of said first ring member being less than a full rotation of said first ring member about said common axis. 
Brojač kao što je navedeno u zahtjevu 5 naznačeno time da se navedeno prvo sredstvo uključenja (704) radijalno deflektira prema van nakon predodređenog stupnja Totacije navedenog prvog prstenastog elementa (201), navedeni predodređeni stupanj rotacije navedenog prvog prstenastog elementa bivajući manji od pune rotacije navedenog prvog prstenastog elementa oko navedene zajedničke osi.
The method according to any one of the preceding embodiments, wherein the amount of SNAC is 100-500 mg SNAC, such as 200-400 mg or 300 mg SNAC. 
Pripravak za uporabu prema zahtjevu 7, naznačen time što količina SNAC iznosi 200-400 mg ili pri čemu količina SNAC iznosi 300 mg.
The present light stabilising composition, when based on a caramelised feedstock obtained by caramelising sugars in the presence of a nitrogen source, will usually contain a significant amount of aminosugars such as glucosamine and fructosamine. 
Sadašnji pripravak za stabiliziranje na svjetlo, kad se bazira na karameliziranoj sirovini dobivenoj karameliziranjem šećera u prisutnosti izvora dušika, će obično sadržavati značajnu količinu aminošećera, kao što su glukozamin i fruktozamin.
Figure 4 is a cut-away perspective view of a gear pump; 
Slika 4 - prikazuje pogled u perspektivi na zupčanu pumpu s izrezanim dijelom;
A composition according to claim 1 or 2, wherein Y is O. 
Pripravak u skladu sa zahtjevom 1 ili 2, naznačen time, da Y je O.
It is expected that the latter activity may be due to the compounds' ability to act as competitive antagonists of DHFR, although details of the mechanism are not presented here. 
Očekuje se da ova druga aktivnost može biti uslijed sposobnosti spojeva da djeluju kao kompetitivni antagonisti DHFR, iako ovdje nisu prikazani detalji mehanizma.
R2b and R2c are independently selected from the group consisting of hydrogen, chloro, fluoro, methyl, trifluoromethyl, cyano, methoxy, and N(CH3)2; n is selected from the group consisting of 0 and 1; and R3 is independently selected from the group consisting of fluoro, chloro, bromo, methyl, trifluoromethyl, cyano, methoxy, and N(CH3)2. 
R» i RC su neovisno odabrane iz skupine koju čine vodik, kloro, fluoro, metil, trifluorometil, cijano, metoksi, i N(CHs)»; n je odabran iz skupine koju čine 01 1; 1 R, je neovisno odabrana iz skupine koju čine fluoro, kloro, bromo, metil, trifluorometil, cijano, metoksi, i N(CH3),.
Goodness-of-fit on F 2 1.042 
Ocjena prilagodbe na F?
84 <10 Process for preparing a fraction enriched with ginkgo terpenes, which comprises subjecting Ginkgo biloba extracts to the following steps: 
Postupak uklanjanja pesticida iz ekstrakta Ginko biloba, naznačen time da se ekstrakt dobiven uobičajenim postupkom podvrgava sljedećim koracima: a)
In another embodiment, the present invention includes the crystalline Form II as defined above, characterized by an x-ray powder diffraction pattern further having at least four peaks expressed as 2θ at 4.48, 9.00, 13.58, 15.62, 16.48, 19.02, 19.44, 22.46 and 25.00±0.2 degrees when measured against an internal silicon standard. 
Kristalni oblik II (R)-7-kloro-N-(kinuklidin-3-il)benzo[b]tiofen-2-karboksamid hidroklorida - monohidrata, karakteriziran praškastim uzorkom raspršenja x-zraka koji ima pikove izražene kao 2 21.38 + 0.20 stupnjeva mjereno prema internom standardu silicija i karakteriziran praškastim uzorkom raspršenja x-zraka koji nadalje ima najmanje četiri pika, šest pikova, osam pikova ili sve pikove izražene kao 2 13.58, 15.62, 16.48, 19.02, 19.44, 22.46 1 25.00 + 0.20 stupnjeva mjereno prema internom standardu silicija.
Use of the pharmaceutical composition of any one of claims 1-8 for the preparation of a medicament for the treatment of a CNS disorder, wherein the amount is effective for treatment of the disorder and wherein administration to the patient results in exhibition of at least one of: 
Upotreba farmaceutskog sastava prema bilo kojem od zahtjeva 1-8 za pripremu lijeka za liječenje poremećaja CNSa, pri čemu je količina djelotvorna za liječenje poremećaja, te davanje pacijentu rezultira sa prikazivanjem najmanje jednog od:
A dermal matrix formulation according to claim 10, wherein the antioxidant is resveratrol. 
Formulacija dermalnog matriksa u skladu s patentnim zahtjevom 10, naznačena time što je antioksidans rezveratrol.
The mouse of claim 1, wherein the endogenous λ (lambda) light chain allele comprises a plurality of human Vλ gene segments. 
Miš prema zahtjevu 1, naznačen time, što se alel endogenog lakog 2 (lambda) lanca sastoji od više humanih segmenata gena VA.
The method of claim 6, wherein the pharmaceutical composition is suitable for oral administration. 
Pripravak prema patentnom zahtjevu 7 koji je pogodan za oralnu ili topičku primjenu.
Published Phase IIb data reveal that SR-141716 dose-dependently reduced body weight in human subjects over a 16 week trial period. 
Objavljeni podaci Faze IIb pokazali su da je smanjenje mase kod ljudi podvrgnutih ispitivanju kroz 16 tjedana ovisilo o SR-141716.
Final weight 249.6 g.The solution was filtered through a 0.45 µm PVDF filter. 
Konačna težina 249.6 g. Otopina je filtrirana kroz 0.45 um PVDF filter.
allow a gravitational flow of wastewater from the source basin to the recipient basin under the influence of gravity when a water level in the source basin is above a water level of the recipient basin; 
(a) omogućava gravitacijski protok otpadne vode iz izvornog bazena u prijemni bazen pod utjecajem gravitacije kada je razina vode u izvornom bazenu iznad razine vode prijemnog bazena;
The method according to claim 1, wherein the disorder or injury is osteoarthritis. 
Farmaceutski pripravak u skladu sa zahtjevom 1, pri čemu bolest zglobova ili tetiva, poremećaj ili ozljeda je osteoartritis.
introducing into said cells a nucleic acid encoding a T-cell receptor (TCR), or a functionally equivalent molecule, as defined in Claims 25 or 26; and 
Nukleinska kiselina koja kodira receptor T stanica (TCR) prema Zahtjevu 17 ili vektor ekspresije sposoban za ekspresiju spomenutog receptora T stanice (TCR).
it is a product of in vitro transcription of a DNA template by an RNA polymerase; 
to je proizvod in vitro transkripcije DNA obrasca RNA polimerazom;
The most common way is to use unsaturated fatty acids, which react with atmospheric oxygen under ambient conditions to form a dry film (e.g. 
Najčešći način je upotreba nezasićenih masnih kiselina, koje pod uvjetima okoline reagiraju s atmosferskim kisikom, pri čemu nastaje suhi film (npr.
Polyoxyethylene fatty acid esters, for example polyoxyethylene stearic acid esters of the type known and commercially available under the trademark MYRJ. 
3) Estere polioksietilen masne kiseline, na primjer estere polioksietilen stearinske kiseline tipa poznatog i komercjalno raspoloživog pod zaštićenim nazivom MYRJ.
and R8' together with the carbon atom to which they are attached form C3-C7ycloalkyl; 
R* je vodik, Cy-Cyalkil, benzil; ili i R* zajedno sa atomom ugljika na koji su vezani tvori C3-C;cikloalkil;
Secondary phases 0 to 30% by weight, preferably 3 to 20% by weight and even more preferably 5 to 10% by weight referred to the total quantity of clinker/cement, wherein the proportions of the phases add up to 100%. 
* sekundarne faze 0 do 30 % mase, pri čemu proporcije faza klinkera iznose ukupno do 100 %, i mljeveni kalcijev sulfoaluminat klinker.
an antisense oligomer which consists of a nucleotide sequence having deletion, substitution, insertion and/or addition of 1 to 5 nucleotides in the nucleotide sequence of SEQ ID NO: 1 or 2, and has an activity to cause skipping of the 51st exon in the human dystrophin gene; and 
antisensni oligomer koji se sastoji od nukleotidne sekvence koja ima deleciju, supstituciju, inserciju i/ili adiciju od 1 do 5 nukleotida u nukleotidnoj sekvenci SEQ ID NO: 1 ili 2, ima aktivnost izazvati preskakanje 51-vog egzona u humanom distrofinskom genu; i
When the mobile station apparatus performs the information-keeping type of mapping, the base station apparatus can transmit, to the mobile station apparatus, the RRC signaling including information indicating a certain amount (keeping value, hereinafter) of resources in which the reception quality information can be mapped. 
Mobilni komunikacijski sustav prema zahtjevu 1, naznačen time da uređaj bazne stanice (100) dodano prenosi, na uređaj mobilne stanice (200), RRC signalizaciju koja sadrži informacije koje ukazuju na unaprijed definiranu količinu resursa u kojima se mogu mapirati informacije o kvaliteti prijema.
The system of claim 1 wherein the elongate wick is slidably engages the at least one inner surface of the electric heater. 
Sustav (10) prema zahtjevu 1, pri čemu izduženi fitilj (30) klizno zahvaća najmanje jednu unutrašnju površinu električnog grijača.
The buprenorphine dimer compound for the use according to claim 6, wherein the patient is a human and wherein the dose administered is 10 to 50 mg daily. 
Dimer buprenorfina za uporabu u skladu sa 6. zahtjevom, pri čemu je pacijent čovjek te primijenjena doza iznosi od 10 do 50 mg dnevno.
According to yet another preferred embodiment of the inventive process, the at least one acid having a pKa of less than or equal to 2.5 is H3PO4, preferably H3PO4 in a concentration of 20% to 40% (v/v). 
Postupak prema bilo kojem od zahtjeva 1 do 3, naznačen time da najmanje jedna kiselina koja ima pK, od manje od ili jednako 2.5 je H3sPOx, poželjno H3PO, u koncentraciji od 20 % do 40 % (v/v).
The compound according to claim 1, wherein the compound is vortioxetine (DL)-pyroglutamate monohydrate in crystalline form with XRPD reflections at 6.16, 9.25, 17.68 and 18.12 (°2θ) (±0.1 °2θ). 
Spoj prema patentnom zahtjevu 1, naznačen time što je vortioksetin (DL)-piroglutamat monohidrat u kristalnom obliku s XRPD refleksijama kod 6,16, 9,25, 17,68 i 18,12 (220) (+0,1 220).
performing of spraying, by means of the liquid spraying component (240), on the front part of said net's (230) outer surface not facing the chiller (100), contrariwise to the chiller (100) and to the incoming direction of air. 
- raspršivanje, uz pomoć komponenta (240) raspršivanja tekućine, na prednjem dijelu spomenute mrežine (230) vanjske površine koja nije okrenuta prednjom stranom prema hladnjaku (100), u smjeru suprotnom kretanju kazaljke na satu u odnosu na hladnjak (100) i u odnosu na dolazni smjer zraka.
A combination comprising an acid addition salt of a compound of the formula (1) which is a lactate salt, and one or more other therapeutic agent. 
Kiselinska adicijska sol spoja formule (1) [image] koja je sol dobivena s mliječnom kiselinom.
The body of the headwear member is preferably formed by molding and the headwear signal conduit means is embedded within the body by the molding. Preferably, the headwear signal conduit means is exposed at a surface part of the headwear member adjacent or within the surface portion of the headwear member defining the headwear connection means, and the attachment means includes signal conduit means arranged to make electrical contact with the headwear signal conduit means when connected to the surface of the headwear member thereby to permit electrical signals to be conveyed between the between the headwear member and the attachment means. 
Slušalice prema bilo kojem od zahtjeva 35 do 37, naznačene time, da je naglavni signalni vod izložen na dijelu površine od školjke za uho, granično ili unutar površinskog odsječka od školjke za uho, koji definira navedeni naglavni spojni uređaj, a navedeni priključni uređaj obuhvaća signalni vod namješten tako, da uspostavlja električni kontakt s navedenim naglavnim signalnim vodom, kada je on spojen na površinu školjke za uho, čime se dopušta prijenos električnih signala između školjke za uho 1 priključnog uređaja.
Medical treatments based on anamorelin 
MEDICINSKI TRETMANI NA BAZI ANAMORELINA
Removal of ethyl acetate gives light brown viscous liquid which is purified by column chromatography (silica gel 230-400 mesh, n-hexane-ethyl acetate, 92:8) to get 3-bromo-5-methoxy-4-octyloxybenzaldehyde. Step-II: 
Uklanjanjem etilacetata dobije se svijetlosmeđa viskozna tekućina, koju se pročisti kromatografijom na stupcu (silikagel veličine čestica 0,066-0,037 mm (230-400 mcsh), n-hcksan/ctil-acctat, 92:8) kako bi se dobilo 3-brom-5-metoksi-4-oktiloksibenzaldehid,
A composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 8, and a pharmaceutically acceptable vehicle. 
Pribor koji sadrži spremnik koji sadrži učinkovitu količinu spoja ili njegove farmaceutski prihvatljive soli prema zahtjevu 1 ili 2.
The reaction mixture was then decanted and poured into water (100 ml) and acidified to pH1 with concentrated hydrochloric acid. 
Reakciona smjesa se tada oddekantira 1 izlije u vodu (100 ml) 1 zakiseli se na pH1 s koncentriranom klorovodičnom kiselinom.
a DNA comprising a nucleotide sequence having a homology of at least 50% with the nucleotide sequence of SEQ ID No 1 and encoding a protein having a fructosyl-transferase activity. 
(c) DNA koja ima nukleotidni slijed homologan najmanje 50% nukleotidu u SEQ ID NO:1 i kodira protein s aktivnošću fruktozil-transferaze.
The reaction mixture containing compound (c) (about 4500 mL) is added and rinsed with tetrahydrofuran (1000 mL). 
Doda se reakcijska smjesa koja sarži spoj (c) (približno 4500 ml), te ispere tetrahidrofuranom (1000 ml).